ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the usage of its “at the market” equity providing program.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti may issue as well as market from time to time its everyday shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were offered at prevailing market prices averaging US$1.0747 per share. No securities had been marketed throughout the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with more freedom in its ongoing review process to enjoy and evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription drugs making use of OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of efficacy and safety for lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that are not statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, along with other unknown variables that might result in the particular results of Acasti to be materially different from historical success or as a result of any future outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, readers are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be forward-looking and uncertain. People are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this press release. Forward-looking statements in that press release include, but aren’t confined to, information or statements about Acasti’s strategy, succeeding operations and the review of its of strategic alternatives.
The forward looking claims contained in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor aisle of Acasti’s site at www.acastipharma.com. All forward looking claims in that press release are manufactured as of the particular date of this press release.
ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a consequence of information that is brand new , future events or otherwise, except as required by law. The forward-looking claims contained herein are also subject typically to assumptions and risks as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage